UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Slc26a4 expression prevents fluctuation of hearing in a mouse model of large vestibular aqueduct syndrome.

Nishio A1, Ito T1, Cheng H2, Fitzgerald TS3, Wangemann P4, Griffith AJ5.
Neuroscience.Neuroscience.2016 Aug 4;329:74-82. doi: 10.1016/j.neuroscience.2016.04.042. Epub 2016 May 4.
SLC26A4 mutations cause fluctuating and progressive hearing loss associated with enlargement of the vestibular aqueduct (EVA). SLC26A4 encodes a transmembrane anion exchanger called pendrin expressed in nonsensory epithelial cells of the lateral wall of cochlea, vestibular organs and endolymphatic s
PMID 27155149

Stent-assisted coil embolization of challenging intracranial aneurysms: initial and mid-term results with low-profile ACCLINO devices.

Tureli D1, Sabet S2, Senol S3, Andac N4, Donmez H3, Geyik S5, Baltacioglu F2, Cekirge S6.
Acta neurochirurgica.Acta Neurochir (Wien).2016 Aug;158(8):1545-53. doi: 10.1007/s00701-016-2839-8. Epub 2016 Jun 2.
BACKGROUND: Stent-assisted coiling using low-profile, self-expandable and retrievable stents is a valid option in endovascular treatment of challenging intracranial aneurysms. This study aims to evaluate the feasibility and efficacy of ACCLINO 1.9 F and ACCLINO Flex stent systems, designed for use
PMID 27250849

Transcatheter Arterial Embolization with n-Butyl Cyanoacrylate for the Treatment of Acquired Uterine Vascular Malformations.

Picel AC1, Koo SJ2, Roberts AC3.
Cardiovascular and interventional radiology.Cardiovasc Intervent Radiol.2016 Aug;39(8):1170-6. doi: 10.1007/s00270-016-1328-z. Epub 2016 Mar 28.
PURPOSE: The purpose of the study was to evaluate the technique and outcomes of transcatheter arterial embolization (TAE) with n-butyl cyanoacrylate (NBCA) for the treatment of acquired uterine arteriovenous malformations (AVMs).MATERIALS AND METHODS: A retrospective review identified five women tre
PMID 27021069

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

Makimoto Go,Ohashi Kadoaki,Senoo Satoru,Hotta Katsuyuki,Maeda Yoshinobu,Kiura Katsuyuki
Internal Medicine 58(11), 1625-1627, 2019
… We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. … She has been effectively and safely treated with osimertinib readministration for over 10 months. … A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR …
NAID 130007658147

渡邉健,吉藤康太,大川龍之介,戸塚実,三浦修,新井文子
臨床血液 59(12), 2555-2560, 2018
症例は24歳男性。T-ALL（acute lymphoblastic leukemia）に対してJapan Adult Leukemia Study Group（JALSG）ALL202-Uに沿った寛解導入療法中L-asparaginase（L-asp）6回目の投与後に重症高triglyceride（TG）血症（4,132 mg/dl）を認め …
NAID 130007554304